Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Radiopharmacology Stories

2012-09-06 02:30:48

BALTIMORE, Sept. 6, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), - is pleased to announce that Jubilant DraxImage Inc. (hereinafter "JDI"), a Jubilant Life Sciences Company, and Positron Corporation (hereinafter "Positron"), have executed a Letter of Intent pertaining to: (a) Positron's supply of Active Pharmaceutical Ingredient (API) grade Sr-82 for the JDI Sr-82/Rb-82 generator; (b) JDI's and Positron's co-promotion of JDI Sr-82/Rb-82 generators to end-users...

2012-08-29 22:23:47

BERLIN, August 30, 2012 /PRNewswire/ -- Innovative medical research in Germany In April 2012, Indian MNC Piramal took over Bayer HealthCare's molecular-imaging pipeline and has since then been continuing research and development work on the acquired PET radiopharmaceuticals in its labs in Berlin. Speaking at a press conference Mr. Ajay Piramal, Chairman of Piramal Group commented on the strategy saying, "Molecular imaging is one of the key technologies paving the way to...

2012-08-22 10:24:31

LUBBOCK, Texas, Aug. 22, 2012 /PRNewswire/ -- Positron Corporation, (OTCBB:POSC) a leading molecular imaging healthcare company, is pleased to announce the submission of a Drug Master File (DMF), with the Federal Drug Administration (FDA), for the production of Active Pharmaceutical Ingredient (API) grade strontium-82, through its wholly owned subsidiary Manhattan Isotope Technology, LLC. A Drug Master File (DMF) is a document submitted to the FDA, which contains complete information on an...

2012-08-20 06:28:15

CHICAGO, Aug. 20, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC) a leading molecular imaging healthcare company, is pleased to announce the FDA's marketing approval of The University of Texas Health Science Center at Houston (UTHealth) Coronary Flow Reserve (CFR) quantification software, cfrQuant(TM). The cfrQuant(TM) software was developed under the guidance of K. Lance Gould, M.D., and the Weatherhead PET Imaging Center of the UTHealth Medical School, with contributions of...

2012-08-16 06:24:59

CHICAGO, Aug. 16, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC) a leading molecular imaging healthcare company is pleased to announce the use of their Attrius system at Caring Heart and Brain Imaging Inc., of Manasquan, New Jersey, which now offers Amyvid PET scans to identify the presence of plaque in the brain, which has been shown to be a precursor to Alzheimer's disease. Amyvid(TM) (Florbetapir F-18 Injection) is indicated for Positron Emission Tomography (PET) imaging of the...

2012-08-08 14:23:45

FARMINGTON, Conn., Aug. 8, 2012 /PRNewswire-iReach/ -- Medical imaging is a highly advanced technology segment in the already-advanced medical diagnostics market, encompassing everything from MRI to CT, from X-Ray to Ultrasound equipment. As the BRIC nations (Brazil, Russia, India, and China) continue their march toward modernization, the market for such advanced equipment will continue to grow. As these economies - and the rest of the world - emerge from recession into a new period of...

2012-08-07 02:29:45

LUBBOCK, Texas, Aug. 7, 2012 /PRNewswire/ -- Positron Corporation (OTCBB:POSC) a leading molecular imaging healthcare company is pleased to announce the consolidation and integration of operations at the Crown Point, Indiana facility to its Lubbock, Texas site. With the acquisition of Manhattan Isotope Technology (MIT), Positron gained the expertise, knowledge and radioactive materials facilities to manage all of the Company's radiopharmaceutical and radioisotope development,...

2012-08-07 02:29:31

LOS ANGELES and SINGAPORE, Aug. 7, 2012 /PRNewswire/ -- ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that it has signed a Master Service Agreement (MSA) with Singapore Radiopharmaceuticals Pte Ltd, a subsidiary of Fortis HealthCare. "This agreement represents an important component of our expansion program in Singapore as we establish R&D and pre-clinical imaging capabilities there," said Christian...

2012-08-06 02:25:59

DULLES, Va. and MUMBAI, India, Aug. 6, 2012 /PRNewswire/ -- IBA Molecular and Piramal Imaging SA (Piramal) have announced an agreement whereby IBA Molecular will manufacture and distribute 18F-Florbetaben, Piramal's new diagnostic imaging agent, in the European and US markets. 18F- Florbetaben is a radiopharmaceutical currently in development for use with positron emission tomography (PET) for the detection of beta-Amyloid plaque deposition in the brain, a pathological feature associated with...

2012-07-31 10:26:19

HOPKINTON, Mass., July 31, 2012 /PRNewswire/ -- Alseres Pharmaceuticals, Inc. (OTC: ALSE) today announced that it has entered into an agreement with Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB, "Navidea") to license, [(123)I]-E-IACFT Injection (CFT), also called Altropane®, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson's disease and movement disorders. "We are pleased to have completed this agreement with Navidea. With its focus,...